Fatal myocardial infarction following therapy with prothrombin complex concentrates in a young man with hemophilia A

A fatal myocardial infarction in a 22-year-old man with hemophilia A and a factor VIII inhibitor is described. The catastrophic event occurred while the patient was receiving high doses of unactivated prothrombin complex concentrates. Autopsy examination revealed myocardial hemorrhage with no eviden...

Full description

Saved in:
Bibliographic Details
Published in:Pediatrics (Evanston) 1984-08, Vol.74 (2), p.279-281
Main Authors: SULLIVAN, D. W, PURDY, L. J, BILLINGHAM, M, GLADER, B. E
Format: Article
Language:English
Subjects:
Adult
Antibody Formation
Biological and medical sciences
Blood Coagulation Factors - adverse effects
Factor VIII - immunology
Hematologic and hematopoietic diseases
Hemophilia A - immunology
Hemophilia A - therapy
Humans
Male
Medical sciences
Myocardial Infarction - chemically induced
Platelet diseases and coagulopathies
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A fatal myocardial infarction in a 22-year-old man with hemophilia A and a factor VIII inhibitor is described. The catastrophic event occurred while the patient was receiving high doses of unactivated prothrombin complex concentrates. Autopsy examination revealed myocardial hemorrhage with no evidence of coronary artery disease or thrombosis. There also was postmortem evidence of previous myocardial infarctions. This is the fourth documented case of myocardial infarction occurring in a young hemophiliac patient using unactivated prothrombin complex concentrates. It is concluded that utilization of prothrombin complex concentrates in hemophiliac patients must be limited and closely monitored. Therapeutic guidelines are recommended.
ISSN:0031-4005
1098-4275
DOI:10.1542/peds.74.2.279